By: Ana Elcarte
BO-112 : Immunotherapie against cancer has completed its first research phase
22/10/2020BO-112, the first spanish immunotherapy has completed the first research phase in patients with immunotherapy-resistant cancer Read complete news here Read More
Algenex inaugurates the new facility to produce vaccines
26/09/2020The new facility can support the production of up to 3.5kg of recombinant protein equivalent to around 100 million vaccine doses... Read More
Vivet and Pfizer: Gene Therapy for Wilson Disease
24/09/2020PARIS- NEW YORK,—September 23, 2020— Vivet Therapeutics, a privately held gene therapy biotech company dedicated to developing treatments for inherited liver... Read More
Axovant and Viralgen Sign Strategic Gene Therapy Partnership
16/09/2020NEW YORK and BASEL, Switzerland, Sept. 15, 2020 -- Axovant Gene Therapies Ltd (NASDAQ: AXGT), a clinical-stage company developing innovative gene... Read More
Algenex will manufacture anticovid vaccines with chrysalis
01/09/2020Read complete article here: http://rsocial.elmundo.orbyt.es/epaper/xml_epaper/El%20Mundo/23_08_2020/pla_25589_Madrid/xml_arts/art_43976145.xml?SHARE=6C23C0F29C6C4F158F7CA6264B486305A825DAB9EDC5CC4E64BAD1EE05FFB08FC565BBFB1370B49326DF37CEB36526063192076CBE185CA3B79428930A4E694135DEEF0D2E0B73867BCA292A0BB37E337A0A5BF450AF7E63832D365985AC4F81 Read More
Viralgen obtains €30 million for the new manufacturing plant
29/07/2020July 2020, San Sebastián - Viralgen Vector Core, chosen to "mass" manufacture the COVID-19 vaccine, which is being developed by Massachusetts... Read More
Sanifit will start a new clinical development program of SNF472
23/07/2020Sanifit to start new clinical development program of SNF472 in End Stage Kidney Disease patients with Peripheral Artery Disease FDA has... Read More
Highlight announces first patient dosed in Phase IIa study in liver metastasis
26/06/2020Madrid, Spain -June 26, 2020: Highlight Therapeutics announces the dosing of the first patient in a Phase IIa clinical evaluation of... Read More
Artax Biopharma announces the Scientific Advisory Board for AX-158
24/06/2020Cambridge, Mass., June 24, 2020-Artax Biopharma, Inc., a biotechnology company focused on transforming autoimmune disease treatment, today announces the formation of... Read More
Artax: Series B Financing Extension for First-in-Class Autoimmune Disease Therapy
04/06/2020Cambridge, MA, June 4, 2020 - Artax Biopharma, Inc., a biotechnology company focused on transforming autoimmune disease treatment, today announces the... Read More